2004
DOI: 10.1016/j.jaad.2003.10.490
|View full text |Cite
|
Sign up to set email alerts
|

A 12-week open-label followed by 4-week double-blind study to determine the safety and efficacy of an extended course of alefacept (LFA-3/igg1 fusion protein) in subjects with chronic plaque psoriasis

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles